InflaRx NV (STU:IF0) Volatility: 142.09% (As of Jun. 25, 2026)


STU:IF0 InflaRx NV STU:IF0
30 GF Score
Price €1.68
! 5 Warning Signs
View Full Analysis

What is InflaRx NV Volatility?

InflaRx NV STU:IF0 +0.72% 30 Volatility is 142.09% as of Jun. 25, 2026. GuruFocus rates STU:IF0 with a GF Score™ of 30/100. The stock has 5 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-25), InflaRx NV's Volatility is 142.09%.

InflaRx NV  (STU:IF0) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

InflaRx NV Volatility Related Terms

STU:IF0 vs IRD, NAUT, RGNX: Volatility Comparison

For the Biotechnology subindustry, InflaRx NV's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Volatility distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Volatility falls into.


STU:IF0
30GF Score
InflaRx NV STU:IF0
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InflaRx NV  (STU:IF0) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 142.09% mean?
InflaRx NV (STU:IF0) has a Volatility of 142.09% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on InflaRx NV and its competitors.
Is InflaRx NV's Volatility too high?
InflaRx NV's current Volatility is 142.09%. Overall, InflaRx NV has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's Volatility compare to IRD and NAUT?
InflaRx NV's Volatility of 142.09% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on InflaRx NV and its competitors. InflaRx NV's current Volatility is 142.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (STU:IF0) has a current Volatility of 142.09%. The current Volatility is 142.09%. InflaRx NV's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For InflaRx NV (STU:IF0), the current Volatility is 142.09% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InflaRx NV Business Description

Other Exchanges IFRX:USAIF0:Germany
Address Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
30GF Score

Get the complete analysis for STU:IF0

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.68
Price